Inhibikase Therapeutics(IKT) - 2024 Q4 - Annual Results

Exhibit 99.1 Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity — New Leadership and Focus on Advancement of IkT-001 into a Late-Stage Clinical Trial Program in Pulmonary Arterial Hypertension — March 27, 2025 — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company innovating small molecule kinase inhibitor therapeutics to treat pulmonary arterial hypertension ("PAH"), today reported financial results for the yea ...